STAA — STAAR Surgical Company

STAAR Surgical Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Sales: $42.6 million, down from $77.4 million year-over-year, primarily due to minimal purchases by distributors in China.
• China Sales: Only $389,000 compared to $38.5 million in the previous year, as distributors consumed existing inventory.
• Sales Excluding China: $42.2 million, reflecting a 9% growth year-over-year.
• Adjusted EBITDA: Loss of $26.4 million, compared to earnings of $5.3 million in Q1 2024, largely due to a $22.7 million restructuring charge.
• Gross Margin: 65.8%, down from 78.9% in the prior year, impacted by higher manufacturing costs and excess inventory reserves.
• Cash Position: $222.8 million at the end of Q1, with expectations to not drop below $140 million in the upcoming quarters.

2. Strategic Updates and Business Highlights

• Management Changes: New CEO Steve Farrell emphasized transparency and strategic growth. Key appointments include Warren Faust as President and Deborah Andrews as Interim CFO.
• Cost Optimization Initiatives: Actions taken to streamline operations include reducing underutilized facilities, marketing savings, and personnel reductions, targeting an SG&A run rate of approximately $225 million by year-end.
• China Strategy: Implemented consignment agreements to mitigate tariff impacts, with inventory positioned in China to meet demand through early 2026.
• EVO+ Lens: Anticipated approval for the new EVO+ lens in China by mid-2025, expected to enhance market competitiveness.

3. Forward Guidance and Outlook

• Sales Recovery: Anticipated normalization of sales in China starting Q3 2025, with expectations to recognize $27.5 million from prior orders.
• Long-term Growth: Confidence in the market for lens-based vision correction remains strong, with a growing prevalence of myopia and increasing demand for premium procedures.
• Gross Margin Target: Aiming for 70% gross margin in the second half of 2025, with a long-term goal of 75-80% as manufacturing efficiencies improve.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant year-over-year drop in sales attributed to the Chinese market, raising concerns about reliance on this region.
• Restructuring Costs: The $22.7 million restructuring charge indicates ongoing operational challenges and the need for a strategic overhaul.
• Tariff Risks: While mitigated in the short term, ongoing geopolitical uncertainties and potential tariff increases remain a concern.
• Competitive Pressures: New entrants in the market, such as iBright, could impact market share, although current uptake has been minimal.

5. Notable Q&A Insights

• China Sales Trends: Distributors reported consistent sales throughout Q1, with expectations for a strong recovery in the second half of 2025.
• Competitive Landscape: New competitors have not significantly impacted sales yet, but management remains vigilant.
• Guidance Withdrawal: The company withdrew previous guidance due to economic uncertainties but expressed optimism about achieving sales targets if conditions remain stable.
• Long-term Market Potential: Management highlighted the vast market opportunity for EVO ICL, with a focus on educating patients and overcoming barriers to adoption.

Overall, STAAR Surgical is navigating a challenging landscape with significant operational adjustments and a focus on long-term growth, particularly in the lens-based vision correction market.